The U.S. Federal Trade Commission approved a modified final order giving London-based Hikma Pharmaceuticals plc 20 more days to complete divestitures required for its $2 billion acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim GmbH, of Ingelheim, Germany.